Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program.

17 Oct 2013

St. Jude Medical completes Nanostim acquisition; leadless pacemaker receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers.

15 Oct 2013

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

5 Oct 2013

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels, reveals research presented at ESC Congress 2013 today by Dr Erik O. Udo from the Netherlands. The findings provide a new reference point for the prognosis of modern pacemaker patients.

2 Sep 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Drinking excessive amounts of cola and eating honey made from the pollen of Rhododendrons can cause unusual syncope (fainting) and symptoms of arrhythmia, report two case studies presented as abstracts at the EHRA EUROPACE 2013 meeting, in Athens 23 to 26 June.

25 Jun 2013

Sorin Group announces CE mark approval, launch of REPLY 200 family of pacemakers with SAM

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today CE mark approval and the European commercial launch of the REPLY 200 family of pacemakers featuring Sleep Apnea Monitoring.

18 Jun 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Fish-related ciguatoxin danger highlighted

Researchers report that 28 cases of ciguatera fish poisoning occurred in New York City during 2010–2011, a greater number than were reported during the preceding 10-year period.

6 Feb 2013

Urgent research needed’ on emergency airway management

Research in JAMA adds to suspicions that advanced airway management techniques may do more harm than good in patients with out-of-hospital cardiac arrest.

16 Jan 2013

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

FDA approves Boston Scientific’s S-ICD system to treat sudden cardiac arrest

The U.S. Food and Drug Administration has granted Boston Scientific Corporation regulatory approval for its S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).

29 Sep 2012

i-gel airway device provides reliable anesthesia ventilation

The i-gel supraglottic airway device provides reliable ventilation in patients under anesthesia, results of a prospective multicentre observational study show.

19 Sep 2012

Hyperoxygenation postsurgery benefits in doubt

Supplementation with 80% fraction of inspired oxygen during surgery does not reduce patients’ risk for surgical site infections, research shows.

19 Jul 2012

Capnography ‘useful adjunct’ to colonoscopy care

Monitoring carbon dioxide levels improves detection of altered respiration and apnea in sedated patients undergoing colonoscopy, show ColCap Study results.

6 Jun 2012

Discovery Labs reports data from SURFAXIN preclinical study on RDS

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.

10 May 2012

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Boston Scientific receives European CE Mark approval for INGENIO family of pacemakers

Boston Scientific Corporation announces CE Mark approval and European market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers.

11 Apr 2012